5:11 PM
 | 
Apr 01, 2014
 |  BC Extra  |  Company News

Janssen submits darunavir/cobicistat NDA

The Janssen Research & Development LLC unit of Johnson & Johnson (NYSE:JNJ) submitted an NDA to FDA for a fixed-dose combination of J&J's HIV drug...

Read the full 110 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >